Page last updated: 2024-08-25

lamifiban and 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid

lamifiban has been researched along with 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carroll, RC; Kouns, WC; Lanza, F; Steiner, B; Wang, XF1

Other Studies

1 other study(ies) available for lamifiban and 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid

ArticleYear
Blocking platelet aggregation inhibits thromboxane A2 formation by low dose agonists but does not inhibit phosphorylation and activation of cytosolic phospholipase A2.
    Thrombosis research, 1997, Oct-15, Volume: 88, Issue:2

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetates; Adenosine Diphosphate; Blood Platelets; Cytoplasmic Granules; Cytosol; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Lysophospholipids; Peptide Fragments; Phosphorylase a; Phosphorylation; Plasma; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Serotonin; Thrombasthenia; Thromboxane A2; Tyrosine; Vasoconstrictor Agents

1997